- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02660242
The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary objective of the protocol is to determine if the administration of mini-dose glucagon administered subcutaneously just before exercise produces better glucose stability than no adjustments for moderate intensity exercise in patients with Type 1 Diabetes (T1D). It will also be assessed whether mini-dose glucagon before exercise produces better glucose stability than basal insulin reductions or extra carbohydrate consumption.
This is a randomized, 4-way crossover trial. The trial will include 16 participants who complete the study.
Each participant will undergo four aerobic exercise sessions (in random order), with different strategies for glucose regulation:
- Control Trial: Fasted exercise, no basal insulin reduction
- Strategy 1: Fasted exercise, basal insulin reduction only (50% reduction in basal rate at 60 minutes before exercise, for the duration of the exercise)
- Strategy 2: Fasted exercise, no basal adjustment + pre-exercise glucose tabs (buccal route-40 grams in total )
- Strategy 3: Fasted exercise, no basal adjustment + pre-exercise mini-dose glucagon (sc)
In all 4 sessions, aerobic exercise will be performed in the fasted state (before a standardized meal) for 45 minuets at ~50-55% of the participant's per-determined aerobic capacity. The participant's pump will be blinded during the control trial, strategy 1, and strategy 3 and an injection of saline will be given during the control trial and strategy 1 so that participant is blinded to strategy.
The primary outcome for this study will be the glycemic response during exercise and early recovery.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Joslin Diabetes Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clinical diagnosis of presumed autoimmune type 1 diabetes, receiving daily insulin
- Age 18-<65 years
- Duration of T1D ≥ 2 years
- Random C-peptide < 0.6 ng/ml
- Using continuous subcutaneous insulin infusion (CSII; insulin pump) for at least 6 months, with no plans to discontinue pump use during the study
- Exercises regularly, i.e. ≥30 minutes moderate or more vigorous aerobic activity X ≥3 times/week
- Body mass index (BMI) <30 kg/m2
Females must meet one of the following criteria:
- Of childbearing potential and not currently pregnant or lactating, and agrees to use an accepted contraceptive regimen as described in the study procedure manual throughout the entire duration of the study; or
- Of non-childbearing potential, defined as a female who has had a hysterectomy or tubal ligation, is clinically considered infertile or is in a menopausal state (at least 1 year without menses)
- In good general health with no conditions that could influence the outcome of the trial, and in the judgment of the investigator is a good candidate for the study based on review of available medical history, physical examination and clinical laboratory evaluations
- Willing to adhere to the protocol requirements for the duration of the study
- Must be enrolled in the T1D Exchange clinic registry or willing to join the registry
Exclusion Criteria:
- One or more severe hypoglycemic episodes in the past 12 months (as defined by an episode that required third party assistance for treatment)
- Active diabetic retinopathy (proliferative diabetic retinopathy or vitreous hemorrhage in past 6 months) that could potentially be worsened by exercise protocol
- Peripheral neuropathy with insensate feet
- Cardiovascular autonomic neuropathy with inappropriate heart rate response to exercise
- Use of non-insulin anti-diabetic medications
- Use of beta-blockers
- Use of agents that affect hepatic glucose production such as beta adrenergic agonists, xanthine derivatives
- Use of Pramlintide
- Currently following a very low calorie or other weight-loss diet
- Participation in other studies involving administration of an investigational drug or device within 30 days or 5 half-lives, whichever is longer, before screening for the current study or planning to participate in another such study during participation in the current study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control
No basal insulin adjustment, no carbohydrate intake (until glucose drops <70 mg/dL).
|
|
Active Comparator: Basal insulin reduction
Basal insulin reduction to 50% five minutes before the start of exercise.
|
Basal insulin reduction to 50% 5 minutes before the start of exercise.
|
Active Comparator: Glucose Tabs
Dextrose tabs orally (20 grams) five minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).
|
Dextrose tabs orally (20 grams) 5 minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).
Other Names:
|
Experimental: G-Pen Mini™ (glucagon injection)
Glucagon (150 µg) five minutes before the start of exercise (SQ-abdomen).
|
Glucagon (150 µg) 5 minutes before the start of exercise (SQ-abdomen).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glycemic Response During Exercise and Early Recovery
Time Frame: 0 to 75 minutes following exercise initiation (0, 5, 10, 15, 25, 35, 45, 50, 55, 60, 75 min)
|
Comparison of glycemic response (from blood glucose) during exercise and early recovery between each exercise strategy.
|
0 to 75 minutes following exercise initiation (0, 5, 10, 15, 25, 35, 45, 50, 55, 60, 75 min)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Hypoglycemia (<70 mg/dL) During Exercise and Early Recovery
Time Frame: 0 to 75 minutes following exercise initiation
|
Comparison of occurrence of hypoglycemia (<70 mg/dL from blood glucose) during exercise and early recovery between each exercise strategy.
|
0 to 75 minutes following exercise initiation
|
Number of Participants With Hyperglycemia (≥250 mg/dL) During Exercise and Early Recovery
Time Frame: 0 to 75 minutes following exercise initiation
|
Comparison of occurrence of hyperglycemia (≥250 mg/dL from blood glucose) during exercise and early recovery between each exercise strategy.
|
0 to 75 minutes following exercise initiation
|
Continuous Glucose Monitor (CGM) Metrics During Late Recovery - Nadir Glucose
Time Frame: 90 min after the standard meal until 1200 noon the day after each exercise session
|
Comparison of nadir glucose from CGM between the exercise strategies.
|
90 min after the standard meal until 1200 noon the day after each exercise session
|
CGM Metrics During Late Recovery - Peak Glucose
Time Frame: 90 min after the standard meal until 1200 noon the day after each exercise session
|
Comparison of peak glucose from CGM between the exercise strategies.
|
90 min after the standard meal until 1200 noon the day after each exercise session
|
CGM Metrics During Late Recovery - Mean Glucose
Time Frame: 90 min after the standard meal until 1200 noon the day after each exercise session
|
Comparison of mean glucose from CGM between the exercise strategies.
|
90 min after the standard meal until 1200 noon the day after each exercise session
|
CGM Metrics During Late Recovery - Coefficient of Variation
Time Frame: 90 min after the standard meal until 1200 noon the day after each exercise session
|
Comparison of the coefficient of variation from CGM between the exercise strategies.
|
90 min after the standard meal until 1200 noon the day after each exercise session
|
CGM Metrics During Late Recovery - Time < 54 mg/dL
Time Frame: 90 min after the standard meal until 1200 noon the day after each exercise session
|
Comparison of percentage of time < 54 mg/dL from CGM between the exercise strategies.
|
90 min after the standard meal until 1200 noon the day after each exercise session
|
CGM Metrics During Late Recovery - Time < 70 mg/dL
Time Frame: 90 min after the standard meal until 1200 noon the day after each exercise session
|
Comparison of percentage of time < 70 mg/dL from CGM between the exercise strategies.
|
90 min after the standard meal until 1200 noon the day after each exercise session
|
CGM Metrics During Late Recovery - Time in Range (70-180 mg/dL)
Time Frame: 90 min after the standard meal until 1200 noon the day after each exercise session
|
Comparison of percentage of time in range (70-180 mg/dL) from CGM between the exercise strategies.
|
90 min after the standard meal until 1200 noon the day after each exercise session
|
CGM Metrics During Late Recovery - Time > 180 mg/dL
Time Frame: 90 min after the standard meal until 1200 noon the day after each exercise session
|
Comparison of percentage of time > 180 mg/dL from CGM between the exercise strategies.
|
90 min after the standard meal until 1200 noon the day after each exercise session
|
CGM Metrics During Late Recovery - Time > 250 mg/dL
Time Frame: 90 min after the standard meal until 1200 noon the day after each exercise session
|
Comparison of percentage of time > 250 mg/dL from CGM between the exercise strategies.
|
90 min after the standard meal until 1200 noon the day after each exercise session
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Michael Riddell, PhD, York University
- Study Chair: Michael Rickels, M.D., M.S., University of Pennsylvania
- Study Chair: Howard Wolpert, M.D., Joslin Diabetes Center
- Principal Investigator: Stephanie DuBose, M.P.H, Jaeb Center for Health Research
Publications and helpful links
General Publications
- Tsalikian E, Mauras N, Beck RW, Tamborlane WV, Janz KF, Chase HP, Wysocki T, Weinzimer SA, Buckingham BA, Kollman C, Xing D, Ruedy KJ; Diabetes Research In Children Network Direcnet Study Group. Impact of exercise on overnight glycemic control in children with type 1 diabetes mellitus. J Pediatr. 2005 Oct;147(4):528-34. doi: 10.1016/j.jpeds.2005.04.065.
- Brazeau AS, Rabasa-Lhoret R, Strychar I, Mircescu H. Barriers to physical activity among patients with type 1 diabetes. Diabetes Care. 2008 Nov;31(11):2108-9. doi: 10.2337/dc08-0720. Epub 2008 Aug 8.
- Chu L, Hamilton J, Riddell MC. Clinical management of the physically active patient with type 1 diabetes. Phys Sportsmed. 2011 May;39(2):64-77. doi: 10.3810/psm.2011.05.1896.
- West DJ, Morton RD, Bain SC, Stephens JW, Bracken RM. Blood glucose responses to reductions in pre-exercise rapid-acting insulin for 24 h after running in individuals with type 1 diabetes. J Sports Sci. 2010 May;28(7):781-8. doi: 10.1080/02640411003734093.
- Rabasa-Lhoret R, Bourque J, Ducros F, Chiasson JL. Guidelines for premeal insulin dose reduction for postprandial exercise of different intensities and durations in type 1 diabetic subjects treated intensively with a basal-bolus insulin regimen (ultralente-lispro). Diabetes Care. 2001 Apr;24(4):625-30. doi: 10.2337/diacare.24.4.625.
- Campbell MD, Walker M, Trenell MI, Jakovljevic DG, Stevenson EJ, Bracken RM, Bain SC, West DJ. Large pre- and postexercise rapid-acting insulin reductions preserve glycemia and prevent early- but not late-onset hypoglycemia in patients with type 1 diabetes. Diabetes Care. 2013 Aug;36(8):2217-24. doi: 10.2337/dc12-2467. Epub 2013 Mar 20.
- Stenerson M, Cameron F, Payne SR, Payne SL, Ly TT, Wilson DM, Buckingham BA. The impact of accelerometer use in exercise-associated hypoglycemia prevention in type 1 diabetes. J Diabetes Sci Technol. 2015 Jan;9(1):80-5. doi: 10.1177/1932296814551045. Epub 2014 Sep 17.
- Tanenberg RJ, Newton CA, Drake AJ. Confirmation of hypoglycemia in the "dead-in-bed" syndrome, as captured by a retrospective continuous glucose monitoring system. Endocr Pract. 2010 Mar-Apr;16(2):244-8. doi: 10.4158/EP09260.CR.
- Campbell MD, Walker M, Trenell MI, Luzio S, Dunseath G, Tuner D, Bracken RM, Bain SC, Russell M, Stevenson EJ, West DJ. Metabolic implications when employing heavy pre- and post-exercise rapid-acting insulin reductions to prevent hypoglycaemia in type 1 diabetes patients: a randomised clinical trial. PLoS One. 2014 May 23;9(5):e97143. doi: 10.1371/journal.pone.0097143. eCollection 2014.
- Taplin CE, Cobry E, Messer L, McFann K, Chase HP, Fiallo-Scharer R. Preventing post-exercise nocturnal hypoglycemia in children with type 1 diabetes. J Pediatr. 2010 Nov;157(5):784-8.e1. doi: 10.1016/j.jpeds.2010.06.004. Epub 2010 Jul 21.
- Riddell MC, Bar-Or O, Ayub BV, Calvert RE, Heigenhauser GJ. Glucose ingestion matched with total carbohydrate utilization attenuates hypoglycemia during exercise in adolescents with IDDM. Int J Sport Nutr. 1999 Mar;9(1):24-34. doi: 10.1123/ijsn.9.1.24.
- Robertson K, Riddell MC, Guinhouya BC, Adolfsson P, Hanas R; International Society for Pediatric and Adolescent Diabetes. ISPAD Clinical Practice Consensus Guidelines 2014. Exercise in children and adolescents with diabetes. Pediatr Diabetes. 2014 Sep;15 Suppl 20:203-23. doi: 10.1111/pedi.12176. No abstract available.
- Camacho RC, Galassetti P, Davis SN, Wasserman DH. Glucoregulation during and after exercise in health and insulin-dependent diabetes. Exerc Sport Sci Rev. 2005 Jan;33(1):17-23.
- Oskarsson PR, Lins PE, Wallberg Henriksson H, Adamson UC. Metabolic and hormonal responses to exercise in type 1 diabetic patients during continuous subcutaneous, as compared to continuous intraperitoneal, insulin infusion. Diabetes Metab. 1999 Dec;25(6):491-7.
- Haymond MW, Schreiner B. Mini-dose glucagon rescue for hypoglycemia in children with type 1 diabetes. Diabetes Care. 2001 Apr;24(4):643-5. doi: 10.2337/diacare.24.4.643.
- Diabetes Research in Children Network (DirecNet) Study Group; Tsalikian E, Kollman C, Tamborlane WB, Beck RW, Fiallo-Scharer R, Fox L, Janz KF, Ruedy KJ, Wilson D, Xing D, Weinzimer SA. Prevention of hypoglycemia during exercise in children with type 1 diabetes by suspending basal insulin. Diabetes Care. 2006 Oct;29(10):2200-4. doi: 10.2337/dc06-0495.
- Rickels MR, DuBose SN, Toschi E, Beck RW, Verdejo AS, Wolpert H, Cummins MJ, Newswanger B, Riddell MC; T1D Exchange Mini-Dose Glucagon Exercise Study Group. Mini-Dose Glucagon as a Novel Approach to Prevent Exercise-Induced Hypoglycemia in Type 1 Diabetes. Diabetes Care. 2018 Sep;41(9):1909-1916. doi: 10.2337/dc18-0051. Epub 2018 May 18.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Immune System Diseases
- Autoimmune Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Hypoglycemia
- Physiological Effects of Drugs
- Gastrointestinal Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Incretins
- Glucagon
- Glucagon-Like Peptide 1
Other Study ID Numbers
- T1DX Mini-dose Exercise
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 1
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Hoffmann-La RocheRoche DiagnosticsCompletedDiabetes Mellitus Type 2, Diabetes Mellitus Type 1Germany
Clinical Trials on Basal Insulin Reduction
-
Institut de Recherches Cliniques de MontrealMcGill University Health Centre/Research Institute of the McGill University...RecruitingType 1 Diabetes MellitusCanada
-
Buckinghamshire Healthcare NHS TrustAnimas CorporationTerminated
-
Mount Sinai Hospital, CanadaCanadian Institutes of Health Research (CIHR); University of TorontoCompleted
-
Assaf-Harofeh Medical CenterUnknown
-
Guillermo Umpierrez, MDMedical University of South Carolina; Sanofi; Texas A&M UniversityCompletedHyperglycemia | Type 2 DiabetesUnited States
-
Mannkind CorporationJaeb Center for Health ResearchActive, not recruitingDiabetes Mellitus, Type 1United States
-
LMC Diabetes & Endocrinology Ltd.CompletedDiabetes Mellitus, Type 2Canada
-
Eli Lilly and CompanyWithdrawnType 2 Diabetes | Type 2 Diabetes Treated With InsulinUnited States
-
Mayo ClinicCompleted